Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Next wave of successful drug therapy strategies in HER2-positive breast cancer

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.05.13
Views: 4992
Rating:

Dr Hans Wildiers - University Hospital Leuven, Gasthuisberg, Belgium

ecancer reporter Peter Goodwin talks to Dr Wildiers at the 2013 IMPAKT conference in Brussels about the latest treatments for HER 2 positive breast cancer, for example combining antiobodies with cytoxics, eg TDM-1.

ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation